The blood-brain and the blood-cerebrospinal fluid barriers: function and dysfunction by Engelhardt, Britta & Sorokin, Lydia
REVIEW
The blood–brain and the blood–cerebrospinal fluid
barriers: function and dysfunction
Britta Engelhardt & Lydia Sorokin
Received: 8 July 2009 /Accepted: 13 August 2009 /Published online: 25 September 2009
# Springer-Verlag 2009
Abstract The central nervous system (CNS) is tightly
sealed from the changeable milieu of blood by the blood–
brain barrier (BBB) and the blood–cerebrospinal fluid
(CSF) barrier (BCSFB). While the BBB is considered to
be localized at the level of the endothelial cells within CNS
microvessels, the BCSFB is established by choroid plexus
epithelial cells. The BBB inhibits the free paracellular
diffusion of water-soluble molecules by an elaborate
network of complex tight junctions (TJs) that interconnects
the endothelial cells. Combined with the absence of
fenestrae and an extremely low pinocytotic activity, which
inhibit transcellular passage of molecules across the barrier,
these morphological peculiarities establish the physical
permeability barrier of the BBB. In addition, a functional
BBB is manifested by a number of permanently active
transport mechanisms, specifically expressed by brain
capillary endothelial cells that ensure the transport of
nutrients into the CNS and exclusion of blood-borne
molecules that could be detrimental to the milieu required
for neural transmission. Finally, while the endothelial cells
constitute the physical and metabolic barrier per se,
interactions with adjacent cellular and acellular layers are
prerequisites for barrier function. The fully differentiated
BBB consists of a complex system comprising the highly
specialized endothelial cells and their underlying basement
membrane in which a large number of pericytes are
embedded, perivascular antigen-presenting cells, and an
ensheathment of astrocytic endfeet and associated paren-
chymal basement membrane. Endothelial cell morphology,
biochemistry, and function thus make these brain micro-
vascular endothelial cells unique and distinguishable from
all other endothelial cells in the body. Similar to the
endothelial barrier, the morphological correlate of the
BCSFB is found at the level of unique apical tight junctions
between the choroid plexus epithelial cells inhibiting
paracellular diffusion of water-soluble molecules across
this barrier. Besides its barrier function, choroid plexus
epithelial cells have a secretory function and produce the
CSF. The barrier and secretory function of the choroid
plexus epithelial cells are maintained by the expression of
numerous transport systems allowing the directed transport
of ions and nutrients into the CSF and the removal of toxic
agents out of the CSF. In the event of CNS pathology,
barrier characteristics of the blood–CNS barriers are altered,
leading to edema formation and recruitment of inflamma-
tory cells into the CNS. In this review we will describe
current knowledge on the cellular and molecular basis of
the functional and dysfunctional blood–CNS barriers with
focus on CNS autoimmune inflammation.
Keywords Blood–brain barrier . Blood–cerebrospinal fluid
barrier . Extracellular matrix . Basement membrane . Choroid
plexus . Experimental autoimmune encephalomyelitis
B. Engelhardt (*)










Semin Immunopathol (2009) 31:497–511
DOI 10.1007/s00281-009-0177-0
Introduction
The central nervous system (CNS) is tightly sealed from
the changeable milieu of blood by the blood–brain barrier
(BBB) and the blood–cerebrospinal fluid (CSF) barrier
(BCSFB). While the BBB is considered to be localized at
the level of the endothelial cells within CNS microvessels,
the BCSFB is established by choroid plexus epithelial
cells. The BBB inhibits the free paracellular diffusion of
water-soluble molecules by an elaborate network of
complex tight junctions (TJs) that interconnects the
endothelial cells. Combined with the absence of fenestrae
and an extremely low pinocytotic activity, which inhibit
transcellular passage of molecules across the barrier, these
morphological peculiarities establish the physical perme-
ability barrier of the BBB. In addition, a functional BBB is
manifested by a number of permanently active transport
mechanisms, specifically expressed by brain capillary
endothelial cells that ensure the transport of nutrients into
the CNS and exclusion of blood-borne molecules that
could be detrimental to the milieu required for neural
transmission.
Finally, while the endothelial cells constitute the physical
and metabolic barrier per se, interactions with adjacent
cellular and acellular layers are prerequisites for barrier
function. The fully differentiated BBB consists of a
complex system comprising the highly specialized endo-
thelial cells and their underlying basement membrane in
which a large number of pericytes are embedded, perivas-
cular antigen-presenting cells, and an ensheathment of
astrocytic endfeet and associated parenchymal basement
membrane. Endothelial cell morphology, biochemistry, and
function thus make these brain microvascular endothelial
cells unique and distinguishable from all other endothelial
cells in the body.
Similar to the endothelial barrier, the morphological
correlate of the BCSFB is found at the level of unique apical
tight junctions between the choroid plexus epithelial cells
inhibiting paracellular diffusion of water-soluble molecules
across this barrier. Besides its barrier function, choroid
plexus epithelial cells have a secretory function and produce
the CSF. The barrier and secretory function of the choroid
plexus epithelial cells are maintained by the expression of
numerous transport systems allowing the directed transport
of ions and nutrients into the CSF and the removal of toxic
agents out of the CSF.
In the event of CNS pathology, barrier characteristics of
the blood–CNS barriers are altered, leading to edema
formation and recruitment of inflammatory cells into the
CNS. In this review we will describe current knowledge on
the cellular and molecular basis of the functional and
dysfunctional blood–CNS barriers with focus on CNS
autoimmune inflammation.
History of brain barriers
The discovery of a vascular barrier between the blood
circulation and the central nervous system dates back more
than 100 years, when in the 1880s Paul Ehrlich discovered
that certain dyes when injected into the vascular system
were rapidly taken up by all organs except the brain and
spinal cord [1]. Ehrlich himself interpreted these findings as
a lack of affinity of the nervous system for these dyes.
However, shortly afterwards Edwin E. Goldman, an
associate of Ehrlich, showed that the very same dyes when
injected into the cerebrospinal fluid readily stained nervous
tissue but not any other tissue [2], suggesting that once
within the CNS the dyes were prevented access to the blood
circulation. Additional studies, demonstrating that neuro-
toxic agents affected brain function only when directly
injected into the brain but not when injected into the
vascular system, further supported the concept of a vascular
blood–brain barrier that also functions as a brain–blood
barrier [3, 4]. Only with the advancement of electron
microscopy was it possible to correlate the ultrastructural
localization of the blood–brain barrier with the capillary
endothelial cells within the brain [5]. Following injection
into the vasculature or into the CNS, the electron-dense
tracer horseradish peroxidase, a small protein of 40 kDa,
was found to diffuse into the intercellular clefts of brain
endothelial cells up to the tight junctions (TJs) between the
endothelial cells. Thus, in vertebrates the inter-endothelial
TJs were recognized as the morphological correlate of the
blood–brain barrier.
There are, however, structures within the brain, located in
the midline of the ventricular system, that lack an endothelial
BBB and are collectively referred to as the circumventricular
organs (CVOs). As CVOs serve neurohemal or neurosecre-
tory functions, i.e. their neurons monitor hormonal stimuli
and other substances within the blood or secrete neuro-
endocrines into the blood, and they lack a vascular barrier
[6]. Rather, capillaries within the CVOs are fenestrated
allowing free diffusion of proteins and solutes between the
blood and the CVOs. Similarly, the endothelial cells of the
choroid plexus do not form a barrier and are fenestrated like
those of the CVOs [7]. The choroid plexus is a villous
structure that extends from the ventricular surface into the
lumen of the ventricles, the major known function of which
is secretion of cerebrospinal fluid. The choroid plexus
consists of an extensive capillary network enclosed within a
single layer of cuboidal epithelium, interconnected by
apical tight junctions, forming a blood–cerebrospinal fluid
barrier (BCSFB). In an analogous manner, a complex
network of tight junctions connecting specialized ependy-
mal cells (tanycytes) seal the CNS from the CVOs [6, 8],
establishing tight junctions as an important structural
element of the blood–brain and blood–CSF barriers.
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The BBB under physiological conditions
Cellular and acellular architecture
As described above at the level of capillaries and
postcapillary venules, the selectively permissive and sealed
phenotype of the endothelial cell monolayer of CNS vessels
is dependent on the complex tight junctions that intercon-
nect adjacent endothelial cells and the low pinoctotic
activity of these endothelial cells. In addition, in CNS
microvessels, the vascular endothelium is ensheathed by a
layer of astrocyte endfeet and associated leptomeningeal
cells that coinvaginate with the endothelium during
development and also contribute to their restricted perme-
ability properties. Ultrastructurally, two basement mem-
branes can be distinguished at the level of smaller vessels,
an endothelial cell basement membrane and an astroglial
basement membrane, which underlie the endothelium and
astrocyte endfeet, respectively (Fig. 1a, b). In addition, the
epithelium of the meninges coinvaginates with blood vessels
from the surface of the brain and contributes to the astroglial
basement membrane [9–11]. The astroglial basement mem-
brane, together with the leptomeningeal basement membrane,
constitutes the parenchymal basement membrane, so-called
because it delineates the border to the brain parenchyma. At
the level of venules and postcapillary venules these endothe-
lial and parenchymal basement membranes are clearly
distinguishable by electron microscopy (Fig. 1b). However,
in brain capillaries they fuse to form one basement membrane
structure [5, 9, 11, 12]. Collectively, these cellular and
acellular layers are considered to constitute the physical
characteristics establishing the limited permeability of the
BBB, and are discussed separately below.
Endothelial cell–cell junctions in the CNS
The inter-endothelial tight junctions in CNS microvessels are
an intricate complex of transmembrane (claudins, occludin,
and junctional adhesion molecule (JAM)-A) and cytoplasmic
(zonula occludens (ZO)-1 and ZO-2, cingulin, AF-6, and
7H6) proteins linked to the actin cytoskeleton [13, 14]
(Fig. 2). Occludin was the first integral membrane protein
described to be exclusively localized within tight junctions
including the BBB [15]. However, mice carrying a null
mutation in the occludin gene are viable and develop
morphologically normal tight junctions in most tissues
including brain microvessels [16], excluding an essential
role in tight junction formation. By contrast, the claudins,
which comprise a gene family of integral membrane tight
junction proteins with 24 members, have been shown to be
sufficient for the formation of tight junction strands [17].
Claudins are not randomly distributed throughout all tissues;
besides the endothelial cell-specific claudin-5, claudin-3 has
been shown to localize to endothelial tight junctions in the
CNS of mice and man [18]. The Ig supergene family
member, JAM-A [19], and the recently discovered endothe-
lial cell-selective adhesion molecule (ESAM)-1, are also
localized in tight junctions [20] of the BBB; however, their
contribution to BBB integrity remains to be determined. The
integral membrane proteins of the tight junctions are linked
to the cytoskeleton via cytoplasmic peripheral membrane
proteins of the MAGUK family, such as ZO-1, ZO-2, and
ZO-3 also within BBB tight junctions (reviewed in [14, 21]).
The primary component of adherens junctions is vascular
endothelial (VE)-cadherin, a Ca2+-regulated protein that
mediates cell–cell adhesion via homophilic interactions
between the extracellular domains of proteins expressed in
adjacent cells [22]. The cytoplasmic tail of VE-cadherin
binds to β-catenin and plakoglobin, which in turn bind via
β-catenin, α-actinin, and vinculin to the actin cytoskeleton,
stabilizing the adherens junction complex. In vascular beds
outside of the CNS, endothelial adherens junctions have
been demonstrated to be important regulators of vascular
permeability (reviewed in [23]), while at the BBB they have
been considered less relevant in regulating BBB paracellular
permeability [24]. However, very recent studies demonstrate
that adhesive interactions of VE-cadherin promote claudin-5
expression by preventing the nuclear accumulation of the
transcriptional regulators, FoxO1 and β-catenin [25]. This
study demonstrates that proper establishment of adherens
junctions is required for expression of claudin-5, which
regulates paracellular permeability of small molecules across
the BBB [25]. Additionally, the adherens junction compo-
nent, β-catenin, is critically involved in the regulation of
tight junctions. Besides its function as a junctional compo-
nent, β-catenin can serve as a transcription factor down-
stream of Wnt-signaling. Induction and maintenance of BBB
characteristics during embryonic and postnatal development
are regulated by Wnt/β-catenin signaling [26]. Endothelial
cell-specific stabilization of β-catenin in vivo enhances BBB
maturation by inducing the expression of claudin-3, whereas
inactivation of β-catenin causes significant downregulation
of claudin-3 and upregulation of plasmalemma vesicle-
associated protein (Plvap), usually present only on immature
brain endothelium or on endothelium of fenestrated capillar-
ies within the CVOs and the choroid plexus [27].
Localized in endothelial cell contacts outside of either tight
junctions or adherens junctions in the brain are molecules like
PECAM-1 and CD99. Mice deficient for PECAM-1 have no
primary defect in BBB integrity, but show a defect in resealing
of the BBB during CNS autoimmune inflammation [28].
Astrocytes, leptomeningeal cells, and pericytes
In addition to the endothelial cell monolayer, CNS micro-
vessels are associated with an ensheathing layer of
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astrocytic glia endfeet and associated leptomeningeal cells.
Grafting studies and data from in vitro BBB models suggest
that inductive influences from astrocytic glia contribute to
the differentiation of the specialized BBB phenotype of the
brain endothelium [29, 30] and reviewed in [31]. While the
precise nature of the BBB inducing factor(s) in the cellular
crosstalk between brain endothelium and astroglial cells are
not yet clear (reviewed in [32]), the fact that these two cell
Fig. 1 Cell and basement membrane layers of CNS blood vessels. a
Schematic representation and immunofluorescence examples of cell
and basement membrane (BM) layers consituting CNS blood vessels.
Larger blood vessels consist of an inner endothelial cell layer with BM
(containing laminins α4 and α5), bordered by the meningeal
epithelium and its BM (containing laminin α1), and an outer astroglial
BM (containing laminin α2) and astrocyte endfeet. Meningeal and
astroglial BMs are collectively termed the parenchymal BM as they
delineate the border to the brain parenchyma. Only at sites of local
inflammation are the endothelial and parenchymal BMs distinguish-
able and define the inner and outer limits of the perivascular space
where leukocytes accumulate before infiltrating the brain parenchyma.
Mononuclear infiltration occurs across endothelial BMs containing
only the laminin α4 and bordered by a parenchymal BM containing
laminin α1 and α2. The BM of microvessels where no epithelial
meningeal contribution occurs have a composite BM containing the
endothelial cell laminins, laminin α4 and α5, and laminin α2 produce
by the astrocytes and deposited at their endfeet. b Electronmicroscopy
showing the endothelial cell and the parenchymal BMs at the level of
smaller blood vessels. Insert shows higher magnification image of
boxed area
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layers are separated by at least one basement membrane at
the level of capillaries and two distinct basement mem-
branes in postcapillary venules and venules, suggests that
these inducing factors are likely to be small molecular
weight molecules. Not fully considered is whether the
basement membrane per se also contributes to the tightness
of the brain endothelial cell monolayer and influences
expression and or function of BBB-specific structural (tight
junctions) and molecular (transporters, enzymes) character-
istics (see below). In addition to astrocytes, epithelial cells
from the meninges can be associated with CNS blood
vessels. While such epithelial cells have been reported to
occur predominantly in association with larger blood
vessels in the human CNS [9, 11, 33, 34], in the mouse
there is data that they may also occur at the level of
postcapillary venules (see below) and hence vessels that
contribute to the microvascular BBB.
Although pericytes cover 99% of the abluminal surface
of the capillary basement membrane in brain, their precise
role in the BBB is not well investigated. Several examples
of human disease suggest that they play an important role in
maintenance of the BBB. CADASIL, for example, is an
inherited angiopathy caused by mutations in the Notch3-
gene, causing loss of pericytes and vessel hypopermeabil-
ity, vessel wall hypotonia, and watershed hypoperfusion
[23]. Furthermore, in vitro BBB models have shown
significantly increased transendothelial electrical resistance
in models incorporating pericytes together with endothelial
cells and astrocytes, as compared to models combining only
endothelial cells and astrocytes [35]. The conspicuous
absence of investigations into the nature of pericyte
contribution to the BBB is due to several factors: difficulty
in extracting pericytes from their tight encasement of ECM
and hence low numbers for in vitro analyses, and the fact
that pericyte markers vary with tissue type suggesting an
important role for the in situ milieu in maintaining their
normal physiological function. Although pericytes in most
tissues can be identified by immunoreactivity for platelet-
derived growth factor (PDGF) receptor β, and desmin or
α-smooth muscle cell actin [36], these are also markers for
other perivascular cells such as smooth muscle cells and
myofibroblasts. Hence, additional markers are required,
which vary with tissue type. In the case of brain pericytes a
combination of positive reaction for PDGFR-β, desmin,
γ-glutamyl transpeptidase [36], Sca-1, nestin and the ATP-
sensitive potassium channel, kir6.1 [37], plus absence of
reactivity for vimentin, glial fibrillary acidic protein and
endothelial cell markers such as PECAM-1 are typical.
During development, the proteoglycan, NG2, provides a
further excellent surface marker that allows visualization of
the entire extension of pericytes on the endothelial plexus
[36]. Improvement in pericyte identification is likely to lead
to increased appreciation of the role of pericytes in the
neurovascular unit. Their important role in establishing a
mature BBB has, however, been shown in mice lacking
PDGF-B. These mice fail to establish pericyte ensheath-
ment of their blood vessels during embryonic development
and develop microaneurysms also in blood vessels of the
CNS [38]. Thus, endothelial PDGF-B retention is required
for proper investment of pericytes in the microvessel wall
including the BBB [39].
Acellular layers—basement membranes
While the cellular components of the BBB have been
relatively well studied, the acellular extracellular matrix
Fig. 2 Endothelial cell–cell
junctions of CNS microvessels.
The scheme shows the junc-
tional molecules localized in the
cell–cell contact of CNS micro-
vessels within tight junctions
and adherens junctions and
outside of these organized junc-
tions. Transmembrane junctional
proteins (names mentioned in
cell 1), scaffolding proteins and
junction associated proteins
involved in mediating the
interaction with the actin cyto-
skeleton (cell 2) are depicted.
The function of the molecules is
described in the text
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components have received little attention. Only relatively
recently have CNS inflammation studies highlighted the
contribution of vascular basement membranes to leuko-
cyte extravasation processes and hence barrier function at
the level of postcapillary venules. In most tissues, with the
exception of secondary lymphoid tissues and the CNS,
two types of extracellular matrix prevail: basement
membranes, complex assemblies of four major glycopro-
tein families, laminins, collagen type IV isoforms, nido-
gens, and heparan sulfate proteoglycans, which underlie
polarized cells such as endothelial and epithelial cells, and
ensheath myogenic tissues, nerves, and adipocytes, the
fundamental function of which is to separate tissue
compartments. The second major extracellular matrix type
is the interstitial matrix of the stroma of tissues which acts
to interconnect rather than separate cellular layers, and is
composed of fibrillar extracellular matrix molecules, such
as collagen types I, III, V, and glycoproteins such as
fibronectin or tenascins.
Comparatively little ECM is found in the brain and its
composition and organization is distinct, with the occur-
rence of unique components. In the CNS there is no need to
generate high levels of tensile or elastic strength usually
resulting from the interstitial extracellular matrix because
the brain is protected by the bony skull, hence, there is little
or no fibrous protein, like collagen types I and III or
fibronectin; and low amounts of glycosaminoglycans
chains, either bound to proteins in the form of proteogly-
cans, or unbound in the form of hyaluronan. The basement
membranes of the vasculature and of the meninges,
therefore, represent the predominant ECM form in the
CNS. Like all basement membranes, those of the CNS
appear as thin, tightly interwoven protein sheets of 20–
200 nm thickness in scanning electron microscopy [40],
and are composed of the laminins, collagen type IV,
heparan sulfate proteoglycans, and the nidogens. However,
all four classes of basement membrane proteins occur in
several isoforms, which can combine differentially to form
biochemically and functionally distinct basement mem-
branes (reviewed in [41]). In addition, basement mem-
branes contain minor components which also contribute to
their overall structure and function; in endothelial cell
basement membranes these include BM40 (osteonectin,
SPARC); fibulin 1 (BM90) and 2; collagen types VIII, XV,
and XVIII; and thrombospondin 1 and 2 [40].
Although data on the basement membrane composition
of CNS vessels exist, the data is fragmentary and lacks
specificity both with regards to vessel type and specific
extracellular matrix isoforms [12, 42–47]. Nevertheless,
existing data suggest that biochemical variations exist
between endothelial and parenchymal basement membranes
and that basement membrane components contribute to
microvessel integrity and function.
Recently, mutations of COL4A1, the gene that codes for
the α1 chain of the most common collagen type IV isoform
([α1(IV)]2 α2(IV)), have been shown to cause intracerebral
hemorrhage of microvessels and porencephaly both in
mouse and human [48, 49]. These data suggest that
collagen type IV isoforms are important for structural
integrity of small vessels, a role that is consistent with its
function in basement membranes of other tissues [50].
The laminin family of basement membrane molecules
have been most extensively studied at the level of cerebral
vessels. As in all endothelial cell basement membranes,
those of CNS vessels contain the laminin α4 and α5 chains
combined with laminin β1 and γ1 chains to form laminin
isoforms 411 and 511, respectively [12, 45] (Fig. 1a). By
contrast, the outer parenchymal basement membrane of
postcapillary venules and venules contains laminin α1 and
α2 chains [12] combined with laminin β1 and γ1 chains to
form laminins 111 and 211 (Fig. 1a). In situ hybridization
studies have shown that CNS endothelial cells are the
source of laminin α4 and α5, while laminin α1 is produced
by the leptomeningeal cells and laminin α2 is produced by
the astrocytes and deposited at their endfeet [12] (Fig. 1a).
In addition, perlecan is the predominant heparan sulfate
proteoglycan in the endothelial cell basement membrane,
while agrin predominates in the parenchymal BM [44, 51].
Whether further differences between the endothelial and
parenchymal basement membranes exist in their expression
of other basement membrane molecules is not yet clear. At
the level of capillaries the combined endothelial/parenchy-
mal basement membrane contains laminin α4, α5, and α2
but no laminin α1, plus perlecan and agrin.
While pericytes are especially abundant in the CNS
microvessels, embedded within the endothelial cell base-
ment membrane, their contribution to the endothelial cell
basement membrane is not clear. Indeed, the extent of
pericyte contribution to the endothelial cell basement
membrane in general remains poorly investigated. In vitro,
pericytes have been reported to secrete laminins and
nidogens and to induce endothelial cells to secrete
basement membrane components [52]. However, the
repertoire of basement membrane components that can be
secreted by pericytes has not been studied, and whether
they can influence endothelial cell basement membrane
secretion in vivo is not clear. Given the important role of
pericytes in the barrier function of microvessels [53] and in
vitro BBB models [35] this is an important open question.
Extracellular matrix receptors
Several ECM receptors have been described on CNS
endothelial cells and astrocyte endfeet, which could
potentially act to anchor these cell layers to their respective
basement membranes and thereby contribute to BBB
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integrity Table 1. However, as for the studies concerning the
extracellular matrix composition of CNS vessels, the data on
ECM receptor expression in association with CNS micro-
vessels remains fragmentary and lacks correlation with
vessel type and cellular layer within the vessel wall. CNS
endothelial cells have been reported to express integrins
α1β1, α3β1, α6β1, and αvβ1/αvβ3, and a major non-
integrin receptor, dystroglycan, of the dystrophin glycopro-
tein complex [54], while astrocytes have been reported to
express integrin α6β4 and dystroglycan (reviewed in [42,
43]), and microglia express αvβ3, αvβ5 [55], and αvβ8
[56, 57]. The potential interaction partners for these receptors
and their localization in endothelial or parenchymal base-
ment membranes of CNS microvessels has not yet been
correlated with receptor expression patterns.
Of all these ECM receptors, there is only evidence for a role
for integrin αvβ8, and the non-integrin receptor, dystrogly-
can, in maintenance of BBB integrity. Although the majority
of integrin αv knockout (KO) embryos die at mid-gestation,
some survive to birth and develop severe cerebral hemor-
rhage, which is not due to endothelial or pericytes defects [58,
59]. Integrin β8 KO mice exhibit a similar phenotype, and
current data suggest that αvβ8-mediated interactions are
required for associations between angiogenic cerebral blood
vessels, neuroepithelial cell, and astrocytes during develop-
ment [56]. Similarly, selective elimination of dystroglycan in
astrocytes results in a prominent reactive gliosis resulting
from disruption of the glia limitans [60], a phenotype
consistent with a defect in BBB formation.
Molecular transport systems across the BBB
Besides the structural components discussed above, which
passively inhibit free diffusion of molecules across the
BBB and thus provide a physical barrier, metabolic barrier
characteristics of brain capillary endothelial cells are
maintained by the expression of high a number of transport
systems and enzymes [61]. Transport proteins, mostly of
the solute carrier family ensure the transport of water-
soluble molecules such as glucose [62] or amino acids [63]
across the BBB from the blood into the CNS. Other
molecules such as insulin and transferrin are specifically
targeted from the blood into the CNS by receptor-mediated
transcytosis across brain capillary endothelial cells [64].
Furthermore, for some but not all cytokines, transport
mechanisms across the BBB have been reported [65].
In addition, efflux transporters such as P-glycoprotein or
multidrug resistance proteins, which are members of the
ABC transporter family, are specifically expressed by brain
microvascular endothelial cells [66]. These efflux trans-
porters efficiently move potentially harmful hydrophilic and
hydrophobic molecules out of the CNS.
The BBB under pathological conditions
As described above, normally the microvessels of the CNS
form an effective barrier to the movement of water-soluble
molecules and cells and only in pathological situations is this
barrier function compromised. One such situation is CNS
autoimmune neuroinflammation, as it occurs in the human
disease multiple sclerosis, and the well-studied animal model
thereof, experimental autoimmune encephalomyelitis (EAE).
Lymphocyte transmigration of endothelial cell monolayers
The CNS is considered immune privileged, i.e. it actively
restricts entry of immune cells into the parenchyma and
Table 1 ECM-binding receptors and potential ligands in basement membranes of the CNS microvascular
Receptor Potential ligandsa Localization of ligand
α1β1 Several collagens; highest affinity for collagen type IV,
but also binds types I, XIII, XVI [120–122]
Endothelial or parenchymal BM of postcapillar venules
or combined endothelial/parenhcymal BM of capillaries
α3β1 Laminin 211 Parenchymal BM of postcapillary venules or combined
endothelial/parenchymal BM of capillaries
Laminin 332 (see α6β4 below)
α6β1 Laminins 411, 511, Endothelial BM
Laminin 111 Parenchymal BM at the level of postcapillary venules only
α6β4 Laminin 332 Not yet reported in CNS vessels in vivo; reported to be
expressed by astrocytes in culture [123]
Dystroglycan Highest affinity for perlecan and agrin; also some
binding to laminins 111 and 211
Perlecan predominates in the endothelial cell BM of
postcapillary venules and agrin in the parenchymal BM
[44]; laminin 111 and 211 exist in the
postcapillary parenchymal BM, and laminin 211 in the
composite endothelial/parenchymal BM of capillaries
a Based on studies using various cell types
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only as a consequence of BBB dysfunction as occurs
during EAE does it become accessible to hematopoietic
inflammatory cells. EAE can be transferred by intravenous
injection of neuroantigen-specific T cell blasts into synge-
neic susceptible recipients [67, 68]. The initial interaction
as well as the G-protein-dependent arrest of circulating
encephalitogenic CD4+ T lymphoblasts and the non-
inflamed BBB requires leukocyte integrin α4β1 and
vascular cell adhesion molecule (VCAM)-1 [69], while
diapedesis across the BBB has been proposed to require
LFA-1–ICAM-1 interactions [70]. Whether BBB tight
junctions are involved in the migration of T cell blasts
across the BBB at this stage is not known.
During EAE, α4β1-integrin/VCAM-1 are critically
involved in leukocyte interaction with the inflamed BBB.
Intravital microscopy studies of brain meningeal vessels
and of the spinal cord microvasculature of mice suffering
from EAE have shown that blocking α4-integrin [71] or
lack of β1-integrin [72] on myelin-specific T cells does not
allow them to maintain stable adhesions with the CNS
microvascular endothelium and thus prohibits their migra-
tion across the BBB resulting in inhibition of EAE [72, 73].
This α4β1-integrin-mediated firm arrest to the inflamed
BBB depends on heterotrimeric G(i)-linked receptors [74];
however, the chemokines and chemokine receptors mediat-
ing leukocyte integrin activation—a prerequisite for firm
adhesion—at the BBB are not well defined [75]. The
molecules mediating tethering and rolling of leukocytes to
the inflamed BBB during EAE are presently controversially
discussed. Although intravital microscopy studies have
demonstrated the involvement of P-selectin and its ligand
PSLG-1 in immune cell rolling in inflamed meningeal brain
venules during EAE [71, 76] or after cytokine application
[74], blocking of these adhesion molecules or their absence
in gene-targeted mice does not influence EAE pathogenesis
[77–81], supporting the view that they are dispensable for
leukocyte interaction with the inflamed BBB during EAE.
Similarly, blocking of α4-integrins or lack of β1-integrins
on myelin-specific T cells also fails to impair to affect
initial capturing and rolling of T cell on the inflamed BBB
[71, 72]. Thus, it remains to be shown which adhesion
receptors mediate this initial step of T cell interaction with
the inflamed BBB during EAE in vivo. Furthermore, the
adhesion molecules involved in leukocyte diapedesis across
the inflamed CNS microvessels during EAE still remain to
be determined. In vitro a critical role for endothelial ICAM-
1 has been demonstrated in T cell diapedesis across brain
endothelium, suggesting the active involvement of BBB
endothelium in this process [82, 83].
Last but not least, the involvement of endothelial tight
junctions in leukocyte recruitment across the BBB during
EAE remains to be understood. During EAE, the selective
loss of claudin-3 immunostaining specifically from tight
junctions of venules surrounded by inflammatory cuffs has
been reported, whereas the localization of the other tight
junction proteins remains unchanged [18], implicating an
involvement of endothelial tight junctions in leukocyte
recruitment across the BBB.
Several other endothelial cell adherens junction mole-
cules have been implicated in leukocyte extravasation in
other tissues, including CD99, CD99L, ESAM-1, and the
JAM family members. The use of knockout mice in
inflammatory models have implicated PECAM-1, CD99L,
JAM-A, and ESAM-1 in extravasation of neutrophils, but
in the case of lymphocytes PECAM-1 and ESAM-1 do not
play a role [84], suggesting that different leukocyte types
may use different molecular mechanisms to penetrate the
endothelial barrier. Most of these molecules have not been
specifically investigated with a focus on the BBB, with the
exception of PECAM-1, which has been studied using
PECAM-1 KO mice, revealing an earlier onset of EAE
symptoms due to an increase in vessel permeability [28].
In addition to paracellular transmigration, especially T cells
have been reported to be able to migrate across endothelial
monolayers in a transcellular manner (reviewed in [85]).
Vesiculo-vacuolar organelles or caveolae have been sug-
gested to be involved in regulating this transcellular
diapedesis of leukocytes [86, 87]. Transmission electron
microscopy on serial ultra-thin sections derived from brains
of mice afflicted with EAE have only reported few sites of
neutrophil extravasation through tight junctions [88]. In
contrast, the majority of studies have demonstrated that
during EAE inflammatory cell recruitment across the BBB
leaves tight junctions morphologically intact (reviewed in
[89]), suggesting that transcellular migration of immune cells
may occur in inflammation in the CNS [90].
Lymphocyte transmigration of endothelial basement
membranes
Upon penetration of the endothelial cell monolayer,
infiltrating leukocytes in the CNS still face several
basement membrane layers, which also act as barriers to
their migration. Recent data suggests that sites of enceph-
alitogenic T lymphocyte penetration of the underlying
endothelial cell basement membrane is determined by its
laminin isoform composition. Due to the specialized double
basement membrane structure of postcapillary venules
discussed above, the precise sites of extravasation can be
identified and characterized. In the course of EAE,
leukocytes first traverse the endothelial cell monolayer
and underlying basement membrane and accumulate focally
to form easily identifiable "perivascular cuffs" between the
inner endothelial and outer parenchymal basement mem-
branes (Fig. 1a). However, only upon leukocyte penetration
of the parenchymal basement membrane and glial limitans
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and entry into CNS parenchyma are disease symptoms
induced [44].
As discussed above, laminin α5 and α4 are the
predominant isoforms located in endothelial cell basement
membranes of CNS vessels. However, at the level of
postcapillary venules and venules in the CNS laminin α5
distribution is patchy and irregular while laminin α4 is
ubiquitously expressed [45]. Extravasation occurs focally,
preferentially at sites containing laminin α4 but little or no
laminin α5 [12, 45]. In vitro studies reveal that laminin α4
supports substantial chemokine-induced transmigration of
encephalitogenic T cells and that integrin α6β1 is essential
for this transmigration. By contrast laminin α5 does not
support encephalitogenic T lymphocyte transmigration, and
when mixed together with laminin α4 shows a dose-
dependent and therefore specific inhibition of migration
across laminin α4 [45]. Although in vitro migration studies
using lymphocytes have been limited, studies involving
naive T lymphocytes have shown similar enhanced migra-
tion across laminin α4 as compared to laminin α5 [91].
In mice lacking laminin α4 [92] there is compensatory
ubiquitous expression of laminin α5 in all endothelial cell
basement membranes of the CNS and no differential
expression in different blood vessel types or regulatory
expression of this chain in response to proinflammatory
cytokines [45]. These laminin α4 knockout mice are less
susceptible to EAE than their wildtype littermates and show
significantly reduced severity of disease symptoms, due to
specific inhibition of T lymphocyte infiltration into the
brain. These data support in vitro experiments, substantiat-
ing the inhibitory role of laminin α5 on T cell transmigra-
tion across endothelial cell basement membranes.
In wild-type mice, laminin α4 is ubiquitously expressed
along the vascular tree and α6β1 is strongly expressed on
all T lymphocytes, hence, laminin α4 and α6β1 alone are
insufficient to explain the focal extravasation pattern
observed in EAE. Rather, data suggests that this focal
extravasation is due to the patchy distribution of laminin α5
in the endothelial basement membrane of postcapillary
venules and it is inhibitory effect on T lymphocyte
transmigration. To date, no correlation has been identified
between sites of low laminin α5 expression the expression
of endothelial cell adhesion molecules, such as VCAM-1,
or endothelial junctional molecules that have been impli-
cated in the extravasation process, which suggests that T
lymphocytes are capable of sensing the laminin content of
endothelial cell basement membrane which in turn deter-
mines the probability of whether or not transmigration will
occur. Whether this also requires integrin α6β1 or other
cellular receptors is not yet clear.
Apart from the disease inducing CD4+ T lymphocytes,
several other leukocyte types also extravasate across CNS
postcapillary venules during EAE, most notably macro-
phages and dendritic cells (DC). While infiltration of
macrophages and dendritic cells is also reduced in laminin
α4 KO mice, the extent of inhibition is significantly less
than that observed for the CD4+ T lymphocytes [45].
Clearly, changes in laminin isoform composition of
endothelial basement membranes may alter the inter-
(within the laminin network) and intra-network interactions
(between laminins and other basement membrane compo-
nents), and thereby the tightness of the network [93, 94].
Such ultrastructural alterations are likely to account for the
lower levels of migration of both T lymphocytes and
macrophages across laminin α5-containing vascular base-
ment membranes into the CNS, but not the more pro-
nounced reduction in activated CD4+ T cell infiltration.
This indicates that basement membrane architecture is not
only a limiting factor in the transmigration process but that
activated CD4+ T lymphocytes utilize different mechanisms
to macrophages and DC to transmigrate basement mem-
branes, which are determined by the basement membrane
laminin composition.
Transmigration of the parenchymal basement membrane
Upon penetration of the endothelial cell monolayer and its
underlying basement membrane extravasating lymphocytes
must traverse the parenchymal basement membrane and
glia limitans before they can enter into the brain parenchy-
ma to induce disease symptoms. In contrast to transmigra-
tion of the endothelial cell basement membrane, T
lymphocyte penetration of the parenchymal basement
membrane correlates with sites of focal matrix metal-
loproteinase (MMP) activity (Fig. 3a).
Although several MMPs have been implicated in EAE,
including MMP-14/MMP-2 [95] and MMP-9 [96] and
possibly also MMP-7 [97], and MMP-8 [98–100], most
data is based on mRNA levels and in situ hybridization
studies. As several proteases, in particular MMPs, exist in
an inactive form that requires in situ activation, mRNA and
protein expression is not sufficient to identify sites of
protease activity. The use of novel techniques that permit
simultaneous in situ zymography for protease activity and
immunofluorescence for identification of cellular or extra-
cellular markers, has revealed that the majority of the
protease activity associated with infiltrating leukocytes is
gelatinase activity (MMP-2 and MMP-9), occurring focally
subjacent to the parenchymal basement membrane at sites
of leukocyte penetration of the CNS [44]. The involvement
of the gelatinases in EAE has been substantiated by
inhibitor studies [101, 102], and current data suggest that
infiltrating CD4+ encephalitogenic T lymphocytes are not
the major source of gelatinases in vivo, but rather
infiltrating macrophages and an additional CNS-resident
cell population [44]. The reason that encephalitogenic T
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cells use different mechanisms to penetrate the endothelial
versus the parenchymal basement membrane may be related
to the basement membrane composition: the parenchymal
basement membrane is biochemically distinct to the
endothelial cell basement membrane, with expression of
laminin α1 and α2 rather than the endothelial cell laminins
α4 and α5. Encephalitogenic CD4+ T cells cannot interact
with these two laminin isoforms, even though they express
the receptors capable of mediating such interactions (α6β1)
[12], suggesting that the extracellular milieu is an important
factor in determining migratory mechanisms in encephali-
togenic T cells [12, 44].
There is increasing evidence that the general digestion of
ECM molecules originally attributed to MMPs does not
hold true for the in vivo situation [103, 104]. Until recently
the method employed to search for substrates of MMPs was
in vitro incubation of potential substrate with proteases;
however, this might be not relevant in the cellular or tissue
context. The development of new protease degradomic
techniques [105, 106] has provided evidence for specific
proteolysis and processing of both cell surface and secreted
factors by MMPs which alters the biological activity of these
substrates. In murine EAE, the gelatinases, MMP-2 andMMP-
9, but not collagenases (MMPs-1, MMPs-3, and MMPs-8),
have been shown to cleave β-dystroglycan, a cell surface
receptor that anchors the astrocyte endfeet to the parenchymal
basement membrane without significantly affecting parenchy-
mal basement membrane components or other ECM-binding
receptors on the astrocyte endfeet, suggesting a subtle and
specific regulatory role for proteases in leukocyte extravasation
[44] (Fig 3b). β-dystroglycan is part of a larger receptor
complex that interconnects the parenchymal basement mem-
brane with the astrocyte cytoskeleton [54]. An integral part of
the receptor complex is α-dystroglycan, which is non-
covalently linked to the membrane spanning β-dystroglycan
subunit and constitutes the link to specific ligands, including
laminins α1 and α2, perlecan, and agrin [107] present in the
parenchymal basement membrane. The strategic cleavage of
β-dystroglycan by MMP-2 and MMP-9 results in the loss of
the connection to the α-dystroglycan and therefore the anchor
to the basement membrane. However, what happens to the
cleaved β-dystroglycan fragment or to the α-dystroglycan
subunit is not clear; both are not detectable in the EAE brains
which, however, may be due to the tools available for their
detection in inflamed tissues [44]. Hence, the potential
persistence of dystroglycan fragments in the parenchymal
Fig. 3 Enzymatic degradation
of dystroglycan in association
with leukocyte recruitment
across the parencyhmal
basement membrane of the
BBB. a Double staining for
CD45 to mark infiltrating
leukocytes and dystroglycan,
showing loss of dystroglycan
from sites of leukocyte penetra-
tion of the parenchymal barrier
in inflammed vessels only.
Arrow marks inflamed vessel. b
In situ gelatin gel zymography
together with anti-CD45
staining show gelatinase activity
subjacent to the parenchymal
border where leukocytes enter
into the CNS parenchyma.
* marks lumen of the vessel
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basement membrane may convey additional signals to the
infiltrating leukocytes or may alter the structural properties of
the parenchymal basement membrane and thereby alter its
stability and/or penetrability. Alternatively, it may be degraded
resulting in a source of bioactive fragments.
In addition to β-dystroglycan cleavage, MMP-2 and
MMP-9 have been implicated in the activation of a
chemotactic (CCL2) signal that is required for T lympho-
cyte migration out of the perivascular cuff, across the
parenchymal basement membrane and glia limitans and into
the brain parenchyma [108]. CCL2 overexpressing mice
show accumulation of leukocytes in the perivascular cuff,
which is overcome by induction of MMP-2 and MMP-9
activity. The precise manner of action is not clear, but
demonstrates that MMPs have multiple effects at the
parenchymal border.
Lymphocyte recruitment across the choroid plexus
The choroid plexus plays a central role in the formation and
regulation of cerebrospinal fluid. The epithelial cells of the
choroid plexus hereby form the direct barrier between the
blood compartment and the CSF, whereas the capillaries
within the choroid plexus parenchyma differ from those of
the brain, because they allow free movement of molecules
across the endothelial cells through fenestrations and
intercellular gaps (reviewed by [109]).
In healthy mice the choroid plexus is composed of a
single layer of cuboidal epithelial cells that surrounds the
central stroma. The apical plasmalemma of the epithelial
cells forms numerous microvilli and some cilia (summa-
rized in [7]; Fig. 4). Directly underneath the microvilli the
adjacent epithelial cells are sealed by tight junctions, which
in freeze-fracture replicas appear as parallel strands similar
to the tight junctions in oligodendrocytic myelin sheaths
[110]. Claudin-11 localizes to both myelin and choroid
plexus epithelial tight junctions [111]. In addition, at least
claudin-1 and claudin-2, together with occludin, have been
described in the choroid plexus epithelial cell tight
junctions of the rat brain [110]. Besides tight junctions
restricting permeability across the chrodip plexus epithelium
these cells also express a broad range of transporters [112].
Epiplexus cells or Kolmer cells can be observed in direct
contact with the epithelial microvilli [7, 113] (Fig. 4).
Although the exact origin of the epiplexus cells has been
debated, there is evidence that they are of monocytic origin as
ultrastructural studies have demonstrated monocyte recruit-
ment via the choroidal vessels and subsequent migration
across the choroid plexus epithelium [114, 115]. Thus, it is
tempting to speculate that like antigen-presenting cells in the
perivascular spaces of the vascular BBB, these cells may
serve as barrier-associated antigen-presenting cells and thus
ensure immunosurveillance of the CNS.
It has been difficult to provide direct evidence for the
possibility of immune cell entry into the CNS across the
BCSFB. Although the choroid plexus shows massive
morphological alterations during EAE [7], supporting its
involvement in EAE pathogenesis, no regular accumulation
of inflammatory cells has been demonstrated within the
choroid plexus parenchyma or at the level of the BCSFB
during EAE. Circulating immune cells would need to first
migrate across the fenestrated choroid plexus capillaries,
entering the parenchyma, which still remains outside of the
CNS (Fig. 4). From there immune cells need to penetrate
the layer of choroid plexus epithelial cells either by passing
through the parallel tight junctions strands or by passing
through the choroid plexus epithelial cells at a transcellular
level. Interestingly, choroid plexus epithelial cells constitu-
tively express the adhesion molecules ICAM-1 and
VCAM-1 polarized to their apical surface [116]. Both
adhesion molecules are upregulated during EAE and can
mediate adhesion of immune cells in vitro [117]; however,
they would not be directly accessible for leukocytes
migrating from the blood into the CSF compartment across
the BCSFB. Furthermore, the molecular mechanisms
required for immune cells to migrate across the vascular
wall of choroid plexus capillaries remain to be defined.
















Fig. 4 The BCSFB in the cho-
roid plexus. Schematic drawing
of the choroid plexus pointing
out the fenestrated capillaries
and the localization of the
BCSFB at the level of choroid
plexus epithelium
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process [118], several studies have failed to detect
expression of E- and P-selectin or ICAM-1 and VCAM-1
at the level of choroid plexus endothelial cells [7, 117].
Nevertheless, there is indirect evidence supporting the
possibility that the choroid plexus may serve as an entry
site for immune cells into the CSF space. A number of
studies have demonstrated enhanced leukocyte counts in
the CSF during EAE and MS. Furthermore, T cells found in
the CSF are mainly central memory T cells and thus distinct
from T cell subpopulations present in the circulation or in
the inflamed brain parenchyma during EAE or MS,
suggesting active recruitment into this compartment [118].
The first molecular evidence for T cell migration into the
CNS via the choroid plexus was provided by a recent study
demonstrating that Th17 cells may penetrate the BCSFB
via CCR6 binding to CCL20 produced by choroid plexus
epithelial but not endothelial cells in rodents and man [119]
and specifically use the choroid plexus as CNS entry site.
Outlook
Although the BBB and the BCSFB can be localized to
highly specialized brain microvascular endothelial cells and
choroid plexus epithelial cells, respectively; it has become
evident that their unique characteristics depend on the
orchestrated interaction of these barrier forming cells with
pericytes and astrocytes in their close vicinity. In addition,
extracellular matrix components are gaining recognition as
novel regulators maintaining brain barrier functions and
controlling leukocyte recruitment into the CNS parenchy-
ma. Hence, in order to fully understand the cellular and
molecular mechanisms involved in the function and
dysfunction of the BBB and the BCSFB we need to look
beyond the cells constituting the barriers, and to consider
also the extracellular matrix networks that the cells lay
down at different levels of these barriers. Besides providing
a molecular anchor for the barrier forming cells, i.e.
endothelial and epithelial cells, astrocytes, and pericytes;
the basement membranes of the brain barriers can influence
development of these cellular layers and/or maintenance of
their normal physiological state, as has been shown for other
tissues. These effects can either result from direct cellular
interactions with defined basement membrane components
or indirectly due to enormous potential of basement
membranes to bind and present soluble growth factors and
chemokines. While knowledge on the cellular and physio-
logical characteristics of the barriers of the brain has
advanced enormously, the contribution of acellular barriers
and soluble mediators remains largely to be investigated;
only by combining these aspects in the future can we fully
understand the molecular mechanisms involved in function
and dysfunction of the BBB and the BCSFB.
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